Ph.D., Chief Scientific Officer, Genocea Biosciences, Inc.
Dr. Flechtner is a pioneer in the development of novel vaccines directed toward T cell immunity, and has more than 20 years of experience in vaccine development, immunology, cancer, and infectious disease. She currently leads Genocea’s efforts to develop T cell-directed immunotherapies against cancer. Under her guidance, the company successfully developed two clinical-stage vaccine candidates for infectious disease, and is poised to file an IND to clinically evaluate a personalized cancer vaccine in early 2018. Dr. Flechtner is an inventor on multiple pending and issued patents and has numerous peer-reviewed publications. Dr. Flechtner performed her post-doctoral work at the Dana Farber Cancer Institute and Harvard Medical School. She holds a Ph.D. in Cellular Immunology and a B.S. in Animal Science from Cornell University. Jessica’s memberships include Women in Bio, the American Association of Immunologists, American Association for Cancer Research, Society for Immunotherapy of Cancer, and American Society for Microbiology.
Presentation Title and Company Description
Immunotherapy Showcase: ATLAS™ – Finding True Neoantigens for Cancer Vaccines
Genocea is applying its proprietary technology platform ATLAS™ to identify clinically relevant T cell antigens based on patients’ own immune responses to their cancers. Genocea expects to file an IND on its first personalized cancer vaccine in early 2018.